| Morella Corporation Limited (1MC) ORDINARY FULLY PAID |
Materials |
$11 |
MT Edon Project Update
|
18 Jun 2025 9:46AM |
$0.017 |
$0.027 |
risen by
58.82%
|
|
1MC - Price-sensitive ASX Announcement
Full Release
Key Points
- Morella Corporation Limited provides an update on the Mt Edon Project in Western Australia.
- A recent drilling program targeted lithium and rare earth elements (REEs) within pegmatite formations.
- Drilling results confirm the presence of lithium-bearing minerals, especially lepidolite.
- Zones with elevated concentrations of REEs were also identified in the drilling program.
- Further exploration activities are planned, including more drilling and geochemical analysis.
- Metallurgical testing will be conducted to assess potential for commercial development.
- The company remains engaged with stakeholders and regulatory bodies as the project progresses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Decidr AI Industries Ltd (DAI) ORDINARY FULLY PAID |
Consumer Staple |
$159 |
Application for quotation of securities - DAI
|
18 Jun 2025 9:46AM |
$0.440 |
$0.495 |
risen by
12.50%
|
|
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$152 |
Lumos Reaches FebriDx CLIA Waiver Study Enrolment Milestone
|
18 Jun 2025 9:45AM |
$0.027 |
$0.165 |
risen by
511.11%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Lumos Diagnostics Holdings Limited announced completion of FebriDx CLIA waiver clinical study enrollment.
- The FebriDx test differentiates between bacterial and viral infections at the point of care.
- Completion of the study enrollment is a critical milestone toward obtaining a CLIA waiver in the United States.
- The CLIA waiver would enable FebriDx to be used in a broader range of healthcare settings.
- The announcement underscores FebriDx's value in aiding clinical decision-making and combating inappropriate antibiotic use.
- Lumos Diagnostics is progressing in its regulatory pathway to expand FebriDx's market access.
- The company emphasizes its commitment to advancing novel diagnostic technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Emyria Limited (EMD) ORDINARY FULLY PAID |
Health Care |
$38 |
Proposed issue of securities - EMD
|
18 Jun 2025 9:44AM |
$0.025 |
$0.047 |
risen by
88%
|
|
| Emyria Limited (EMD) ORDINARY FULLY PAID |
Health Care |
$38 |
Medibank to Fund Emyria's PTSD Program at Perth Clinic
|
18 Jun 2025 9:44AM |
$0.025 |
$0.047 |
risen by
88%
|
|
EMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Emyria Limited announces partnership with Medibank to fund PTSD program at Perth Clinic.
- Collaboration targets improved mental health care for PTSD patients.
- Funding supports trial and implementation of Emyria's therapies and care models.
- Program aims to expand access to innovative PTSD treatment.
- Partnership will provide clinical data and advance Emyria's clinical programs.
- Patients are expected to benefit from enhanced treatment options.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| archTIS Limited (AR9) ORDINARY FULLY PAID |
Information Technology |
$32 |
AR9 Enters UK Market with Defence Industry Award
|
18 Jun 2025 9:44AM |
$0.135 |
$0.067 |
fallen by
50.37%
|
|
| Emyria Limited (EMD) ORDINARY FULLY PAID |
Health Care |
$38 |
Proposed issue of securities - EMD
|
18 Jun 2025 9:44AM |
$0.025 |
$0.047 |
risen by
88%
|
|
| Staude Capital Global Value Fund Limited (GVF) ORDINARY FULLY PAID |
Financials |
$270 |
GVF announces a Share Purchase Plan
|
18 Jun 2025 9:44AM |
$1.345 |
$1.335 |
fallen by
0.74%
|
|
GVF - Price-sensitive ASX Announcement
Full Release
Key Points
- GVF announced a Share Purchase Plan (SPP) for eligible shareholders.
- Shareholders can purchase up to $30,000 of new shares under the SPP.
- The issue price will be determined based on a specified methodology detailed in the plan.
- The SPP is designed to give shareholders greater flexibility and improve liquidity.
- Eligibility criteria and key dates for participation are outlined in the announcement.
- The SPP is part of GVF's ongoing capital management strategy.
- The Board believes the SPP will benefit shareholders and aligns with the fund’s long-term objectives.
- The document details application procedures and key contacts for queries regarding the SPP.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Turaco Gold Limited (TCG) ORDINARY FULLY PAID |
Materials |
$669 |
Proposed issue of securities - TCG
|
18 Jun 2025 9:43AM |
$0.485 |
$0.635 |
risen by
30.93%
|
|
| Viva Leisure Limited (VVA) ORDINARY FULLY PAID |
Consumer Discretionary |
$146 |
The Viva Story 2025
|
18 Jun 2025 9:43AM |
$1.315 |
$1.480 |
risen by
12.55%
|
|
VVA - Price-sensitive ASX Announcement
Full Release
Key Points
- Viva Leisure Limited launched 'The Viva Story 2025' as a strategic roadmap for future growth.
- The company operates several fitness brands, including Club Lime, hiit republic, and Plus Fitness.
- Focus on enhancing member experiences through technology and personalized services.
- Strategic acquisitions and organic growth have expanded Viva’s national presence.
- Financial highlights demonstrate strong revenue and membership growth.
- The plan includes sustainability and social responsibility initiatives.
- Leadership changes and governance improvements are outlined to support expansion.
- Targets for 2025 include significant increases in clubs, members, and revenue.
- Commitment to innovation and value-driven leadership is emphasized.
- The strategy includes ongoing investment in technology platforms and operational efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Turaco Gold Limited (TCG) ORDINARY FULLY PAID |
Materials |
$669 |
Placement Introduces Leading Funds to Drive Growth of Afema
|
18 Jun 2025 9:43AM |
$0.485 |
$0.635 |
risen by
30.93%
|
|
TCG - Price-sensitive ASX Announcement
Full Release
Key Points
- Turaco Gold Limited announced a placement to leading funds to drive growth at the Afema Gold Project.
- The placement will introduce new institutional and sophisticated investors to Turaco’s share register.
- Funds raised will be used to accelerate exploration and development at Afema.
- Recent drilling at Afema has identified high-grade gold mineralization, expanding the project’s resource base.
- Updated mineral resource estimates for Afema have been announced.
- The placement strengthens Turaco’s financial position and supports ongoing project development.
- Management highlighted the strategic importance of the placement and the support from shareholders.
- The announcement outlines the placement structure, use of funds, and Afema project highlights.
- Turaco’s broader exploration portfolio in Côte d’Ivoire is also described.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| S2 Resources Limited (S2R) ORDINARY FULLY PAID |
Materials |
$31 |
Application for quotation of securities - S2R
|
18 Jun 2025 9:42AM |
$0.071 |
$0.059 |
fallen by
16.90%
|
|
| Viva Leisure Limited (VVA) ORDINARY FULLY PAID |
Consumer Discretionary |
$146 |
Viva launches new Corporate brand with The Viva Story
|
18 Jun 2025 9:42AM |
$1.315 |
$1.480 |
risen by
12.55%
|
|
VVA - Price-sensitive ASX Announcement
Full Release
Key Points
- Viva Leisure Limited has launched a new corporate brand called 'Viva.'
- The rebranding includes the introduction of 'The Viva Story' to articulate the company's evolution and purpose.
- Strategic reasons for rebranding include organizational growth, better alignment of business units, and improved stakeholder clarity.
- Viva’s vision is to be the leading provider of health and wellness experiences.
- The rebranding initiative encompasses changes to signage, online presence, and member communications.
- The company stresses that its commitment to quality, community, and innovation will remain central post-rebrand.
- Stakeholders, including members and investors, can expect a unified and consistent brand experience.
- The transition process is structured to ensure minimal disruption and clear communication throughout.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Askari Metals Limited (AS2) ORDINARY FULLY PAID |
Materials |
$8 |
Askari Provides Operational and Activities Update
|
18 Jun 2025 9:40AM |
$0.006 |
$0.010 |
risen by
66.67%
|
|
AS2 - Price-sensitive ASX Announcement
Full Release
Key Points
- Operational update centers on the Yarrie Lithium Project (AS2) in Western Australia.
- Land access agreements have been secured, enabling imminent drilling activities.
- Ongoing fieldwork across the company's Western Australian portfolio.
- Progress in project permitting and environmental assessments.
- Engagement with Indigenous stakeholders to ensure responsible exploration.
- Corporate actions include successful capital raising to fund exploration.
- AS2 remains Askari's flagship project, with strong focus and resource allocation.
- Company maintains a solid financial position to support planned activities.
- Plans for further exploration and potential project expansion are underway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Patrys Limited (PAB) ORDINARY FULLY PAID |
Health Care |
$14 |
Section 708A Cleansing Statement
|
18 Jun 2025 9:40AM |
$0.001 |
$0.026 |
risen by
2,500%
|
|
| European Lithium Limited (EUR) ORDINARY FULLY PAID |
Materials |
$386 |
CRML secures US$120M LOI for development of Tanbreez Project
|
18 Jun 2025 9:40AM |
$0.044 |
$0.225 |
risen by
411.36%
|
|
EUR - Price-sensitive ASX Announcement
Full Release
Key Points
- CRML, a subsidiary of European Lithium Limited, secured a US$120 million LOI for the Tanbreez Rare Earth Project in Greenland.
- The LOI is non-binding and from an undisclosed strategic investor.
- Funding will be used for the development and advancement of the Tanbreez Project.
- The project aims to supply rare earth elements (REE) and reduce dependence on China.
- Phased investment is subject to satisfactory due diligence and execution of a formal agreement.
- The Tanbreez Project is considered one of the largest REE deposits globally.
- This funding milestone supports European Lithium’s strategy to become a leading non-Chinese supplier of critical minerals.
- The LOI is a positive step toward final investment decisions and project development in Greenland.
- European Lithium continues work on permitting, technical studies, and securing further strategic partners.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| X2M Connect Limited (X2M) ORDINARY FULLY PAID |
Information Technology |
$5 |
Proposed issue of securities - X2M
|
18 Jun 2025 9:39AM |
$0.022 |
$0.004 |
fallen by
81.82%
|
|
| X2M Connect Limited (X2M) ORDINARY FULLY PAID |
Information Technology |
$5 |
Proposed issue of securities - X2M
|
18 Jun 2025 9:39AM |
$0.022 |
$0.004 |
fallen by
81.82%
|
|
| X2M Connect Limited (X2M) ORDINARY FULLY PAID |
Information Technology |
$5 |
Placement
|
18 Jun 2025 9:39AM |
$0.022 |
$0.004 |
fallen by
81.82%
|
|
X2M - Price-sensitive ASX Announcement
Full Release
Key Points
- X2M Connect Limited announced a successful placement to raise gross proceeds of $2.48 million via the issue of 36,470,588 new fully paid ordinary shares at $0.068 per share.
- The placement was strongly supported by existing shareholders and new investors, including institutional and sophisticated investors.
- Funds raised will be used to support continued growth in core markets, technology development, working capital, and to repay the company's debt facility.
- The placement price represents an 11.7% discount to the last closing price and a 10.6% discount to the 10-day VWAP prior to the announcement.
- Settlement of shares under the placement is expected to occur on 18 June 2024, with quotation on the ASX from 19 June 2024.
- Directors and management of X2M have agreed to participate in the placement, subject to shareholder approval.
- The company continues to focus on expansion within its core markets in Asia and is investing in technology to support its growth objectives.
- The placement is not subject to shareholder approval except for the participation by directors and management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Yowie Group Ltd (YOW) ORDINARY FULLY PAID |
Consumer Staple |
$3 |
Director Appointment/Resignation
|
18 Jun 2025 9:37AM |
$0.014 |
$0.014 |
fallen by
0%
|
|
| Bass Oil Limited (BAS) ORDINARY FULLY PAID |
Energy |
$23 |
Operations Update - May 2025
|
18 Jun 2025 9:36AM |
$0.030 |
$0.062 |
risen by
106.67%
|
|
BAS - Price-sensitive ASX Announcement
Full Release
Key Points
- Bass Oil Limited presented an operations update for May 2025.
- The document details production volumes and operational performance in key regions.
- Recent achievements and current projects are highlighted, including exploration and field development.
- The update addresses challenges and market conditions impacting operations.
- Strategic plans for future exploration, production increases, and corporate growth are outlined.
- Financial and operational results are summarized for stakeholders.
- The regulatory environment and market outlook for Bass Oil are reviewed.
- The report provides a forward-looking statement on company priorities and expected developments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NEXTDC Limited (NXT) ORDINARY FULLY PAID |
Information Technology |
$8,116 |
Debt Facilities increase to A$5.1 billion
|
18 Jun 2025 9:36AM |
$13.980 |
$12.665 |
fallen by
9.41%
|
|
NXT - Price-sensitive ASX Announcement
Full Release
Key Points
- NEXTDC Limited increased its senior debt facilities to A$5.1 billion.
- The upsizing supports ongoing data center expansion and growth.
- Debt facilities arranged through a syndicate of domestic and international banks.
- Provides enhanced financial flexibility and lowers average cost of debt.
- Refinancing and expansion align with NEXTDC’s strategy to fund digital infrastructure development.
- Ensures NEXTDC is well capitalized for future growth and customer demand.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Javelin Minerals Limited (JAV) ORDINARY FULLY PAID |
Materials |
$28 |
JAV appoints experienced geologist and resources director
|
18 Jun 2025 9:35AM |
$0.003 |
$0.105 |
risen by
4,100%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$456 |
Study confirms NB-UVB needed to activate repigmentation
|
18 Jun 2025 9:35AM |
$9.760 |
$9.080 |
fallen by
6.97%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Clinuvel Pharmaceuticals announced confirmation that NB-UVB is required for repigmentation in vitiligo patients.
- SCENESSE® (afamelanotide) was studied in combination with NB-UVB phototherapy.
- The study found that SCENESSE® alone is insufficient to induce repigmentation; NB-UVB must be used.
- This finding has clinical implications for the treatment of vitiligo and supports the use of combination therapies.
- Clinuvel plans to communicate these results to regulatory authorities and the medical community.
- Further research and studies are planned based on these findings.
- The announcement provides details on the study's methodology and key results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Beforepay Group Limited (B4P) ORDINARY FULLY PAID |
Financials |
$71 |
Appointment of Chief Financial Officer
|
18 Jun 2025 9:32AM |
$1.500 |
$1.425 |
fallen by
5%
|
|
Call 1300 880 160
Start a chat
Schedule a call
